HEALTH RELATED QUALITY OF LIFE ASSESSMENT USING ST. GEORGE'S RESPIRATORY QUESTIONNAIRE IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE PATIENTS ON COMBINED INHALED CORTICOSTEROIDS AND BRONCHODILATORS
Keywords:Chronic obstructive pulmonary disease, Bronchodilators, Health-related quality of life, Inhaled corticosteroids, Nil
Objective: Chronic diseases like COPD have significant effects on patient's health-related quality of life (HRQoL). HRQoL measures additional indices as compared to objective measurements like spirometry. Our aim is to assess and compare the disease-specific quality of life in Chronic Obstructive Pulmonary Disease patients using St. George's Respiratory Questionnaire (SGRQ-C) receiving Salmeterol/Fluticasone (SF), Formoterol/Budesonide (FB), Formoterol/Fluticasone (FF).
Methods: A prospective, open-label, randomized, parallel group study conducted at a tertiary care teaching hospital in South India. A 6-months follow-up of 90 patients with severe and very severe COPD randomized to receive Salmeterol/Fluticasone, Formoterol/Budesonide, and Formoterol/Fluticasone in appropriate doses according to their global initiative for chronic obstructive lung disease (GOLD) severity. After spirometry, St. George's Respiratory Questionnaire (SGRQ-C) was administered at baseline and after 180 d to assess improvement in lung function and HRQoL. Statistical analysis used: Data analyzed using SPSS version: 13.0. General linear repeated measures using the post-hoc Bonferroni method assessed significance between treatment groups.
Results: Significant decrease (P<0.05) in each SGRQ-C domains and total scores as well as improvement in FEV1 (P<0.05) was observed in all study subjects. The mean SGRQ-C total score for the group I subjects (SF) at the initial visit was 86.69 and the scores reduced to 58.78 at final visit (i.e. after using SF for 6 mo). This reduction was highly significant statistically (t=10.989, p=0.000) at 95% CI. The mean SGRQ-C total scores for group II subjects (FB) at initial visit were 85.85 and the scores reduced to 67.98 at the final visit. This reduction was highly significant statistically (t=9.669, p=0.000) at 95% CI. The mean SGRQ-C total scores for group III subjects (FF) at initial visit were 83.96 and the scores reduced to 70.37 at final visit (after 6 mo). This reduction was highly significant statistically (t=12.285, p=0.000) at 95% CI.
Conclusion: Maximum improvement in HRQoL (P<0.05) was noted in patients receiving Salmeterol/Fluticasone with respect to SGRQ-C (activity, impact and total) scores and FEV1. This improvement with SF was due to its greater effect in patients with severe and very severe chronic obstructive pulmonary disease. There was a significant improvement in QoL with SF as compared to FB and FF in severe and very severe COPD patients. Subsequently, the three combined inhaled corticosteroids and bronchodilators showed similar improvements in lung functions and Health related quality of life throughout the study.
Hawthorne G, Richardson J, Osborne R. The assessment of quality of life (AQoL) instrument: a psychometric measure of health-related quality of life. Quality Life Res 1999;8:209-24.
E Stahl, A Lindberg, S Jansson. Health-related quality of life is related to COPD disease severity, Health Qual. Life Outcomes 2005;3:56â€“57.
Donohue JF, Noord JA, Bateman ED, Langley SJ, Lee A, Witek TJ, et al. A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium and salmeterol. CHEST J 2002;122:47-55.
Lindberg, A Jonsson, E Ronmark. The ten-year cumulative incidence of COPD and risk factors for incident disease in the asymptomatic cohort. CHEST J 2005;127:1544â€“52.
R Pauwels, A Buist, P Calverley. The GOLD scientific committee. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO global initiative for chronic obstructive lung disease (GOLD) workshops summary. Am J Respir Crit Care Med 2001;163:1256â€“76.
Adams N, Bestall JM, Lasserson TJ, Jones PW. Fluticasone versus beclomethasone or budesonide for chronic asthma in adults and children. Cochrane Library 2006;3:2-3.
Berend N, Kellett B, Kent N, Sly PD. Improved safety with equivalent asthma control in adults with chronic severe asthma on high dose Fluticasone propionate. Respirology 2001;6:237-46.
Casaburi R, Mahler DA, Jones PW, Wanner A, Pedro GS, ZuWallack RL, et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002;19:217-24.
Oga T, Nishimura K, Tsukino M, Sato S, Hajiro T, Mishima M. Comparison of the responsiveness of different disease-specific health status measures in patients with asthma. CHEST J 2002;122:1228-33.
Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A self-complete measure of health status for chronic airflow limitation: The St. George's respiratory questionnaire. Am Rev Respir Dis 1992;145:1321-7.
Miller MR, Crapo R, Hankinson J, Brusasco V, Burgos F, Casaburi R, et al. ATS/ERS task force on standardization of lung function testing: general considerations for lung function testing. Eur Respir J 2005;26:153-61.
Thomas S, Parthasarathi G, Palaksha S, Jayaraj BS, Gowda HB, Mahesh PA. Quality of life assessment in asthmatic patients receiving fluticasone compared with equipotent doses of beclomethasone or budesonide. Lung India 2005;22:86-91.
Global Initiative for Chronic Obstructive Lung Disease [GOLD]. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease; 1998.
Neil Barnes Relative safety and efficacy of Inhaled steroidsâ€. J Allergy Clin Immunol 1998;101: S460-4.
G Guyatt, D Feeny, D Patrick. Measuring health-related quality of life. Ann Intern Med 1993;118:622â€“9.
Dal Negro RW, Pomari C, Tognella S. Salmeterol and fluticasone 50 Î¼g/250 Î¼g bid in combination provides a better long-term control than salmeterol 50 Î¼g bid alone and placebo in COPD patients already treated with theophylline. Pulm Pharmacol Ther 2003a;16:241â€“6.
Gagnon YM, Levy AR, Spencer MD. Economic evaluation of treating chronic obstructive pulmonary disease with inhaled corticosteroids and long-acting beta2-agonists in a health maintenance organization. Respir Med 2005;99: 1534â€“45.